Genome-wide cell-free DNA methylation profiling in advanced stage ovarian cancer.Are we looking at the tumor or the patient's immune response to the tumor?

Cancer Treatment and Research Communications, Journal Year: 2025, Volume and Issue: unknown, P. 100903 - 100903

Published: March 1, 2025

The aim of this study was to identify differentially methylated regions in cell-free DNA (cfDNA) between healthy persons and patients with advanced stage ovarian cancer (ASOC) differences cfDNA methylation before after cytoreductive surgery. Plasma-derived analyzed by a high-throughput genome wide sequencing technique: MeD-seq. A training set therapy naïve samples ASOC (≥FIGO IIIB, n=10) compared controls (n=10) define specific signature. cumulative hypermethylation score constructed validation pre- postoperative 39 were using score. MeD-seq results tumor tissue correlated results. Patients showed clear distinct signature from (p<0.0001). This cfDNA-methylation resulted preoperative scores (135; interquartile range 110-163) that significantly higher than (91; 76-101) (p<0.001). at baseline differed more closely related immune-related cells (T-lymphocytes, neutrophil granulocytes, monocytes, B-lymphocytes) tissue. provides promising method for profiling cfDNA. could clearly be distinguished postoperatively.

Language: Английский

Research Advances in Systemic Inflammatory Indicators in Ovarian Cancer

Journal of Clinical Personalized Medicine, Journal Year: 2025, Volume and Issue: 04(02), P. 835 - 842

Published: Jan. 1, 2025

Language: Английский